Century Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 14, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 14, 2024

IPSC$1.68-7.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)


· · For the Year Ended · · For the Year Ended ·
· · December 31, 2023 · · December 31, 2022 ·

Collaboration revenue	$2,235	$5,199

Operating expenses
Research and development	92,710	97,173
General and administrative	34,706	31,857
In-process research and development	5,000	10,000
Impairment of long-lived assets	16,365	—
Total operating expenses	148,781	139,030

Loss from operations	(146,546)	(133,831)

Interest expense	(540)	(1,430)
Interest income	12,677	4,420
Other expense	(383)	—
Total other income (expense)	11,754	2,990
Loss before provision for income taxes	(134,792)	(130,841)
Provision for income taxes	(1,881)	(91)
Net loss	$(136,673)	$(130,932)

Net loss per common shareBasic and Diluted	(2.30)	(2.27)
Weighted average common shares outstandingBasic and Diluted	59,314,389	57,755,842
Other comprehensive loss
Net loss	$(136,673)	$(130,932)
Unrealized gain (loss) on investments	2,602	(1,786)
Foreign currency translation (loss)	(32)	(26)
Comprehensive loss	$(134,103)	$(132,744)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.